A randomized placebo-controlled trial of delayed-release dimethyl fumarate in patients with relapsing-remitting multiple sclerosis from East Asia and other countries

BACKGROUND: Delayed-release dimethyl fumarate (DMF) has demonstrated efficacy and a favorable benefit-risk profile in phase 2 and 3 studies that enrolled predominantly white patients with relapsing-remitting multiple sclerosis (RRMS). In this study (APEX, Part I), we evaluated the efficacy/safety ou...

Descripción completa

Detalles Bibliográficos
Autores principales: Saida, Takahiko, Yamamura, Takashi, Kondo, Takayuki, Yun, Jang, Yang, Minhua, Li, Jie, Mahadavan, Lalitha, Zhu, Bing, Sheikh, Sarah I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6322309/
https://www.ncbi.nlm.nih.gov/pubmed/30616596
http://dx.doi.org/10.1186/s12883-018-1220-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6322309/
https://www.ncbi.nlm.nih.gov/pubmed/30616596
http://dx.doi.org/10.1186/s12883-018-1220-3

Ejemplares similares